Preliminary findings of a phase I dose-escalation study of sunitinib in combination with gemcitabine plus cisplatin in advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Reck, M. [1 ]
Frickhofen, N. [2 ]
Gatzemeier, U. [1 ]
Fuhr, H. G. [2 ]
Lanzalone, S. [3 ]
Wang, E. [4 ]
Chao, R. [4 ]
Felip, E. [5 ]
机构：
[1] Hosp Grosshansdorf, Dept Thorac Oncol, Grosshansdorf, Germany
[2] Dr Horst Schmidt Klin, Wiesbaden, Germany
[3] Pfizer Italia, Milan, Italy
[4] Pfizer Inc, Global Res & Dev, La Jolla, CA USA
[5] Vall Hebron Univ Hosp, Dept Oncol, Barcelona, Spain
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71435-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6607
引用
收藏
页码：390 / 390
页数：1
相关论文
共 50 条
  • [1] Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study
    Reck, Martin
    Frickhofen, Norbert
    Cedres, Susana
    Gatzemeier, Ulrich
    Heigener, David
    Fuhr, Heinz-Georg
    Thall, Aron
    Lanzalone, Silvana
    Stephenson, Patricia
    Ruiz-Garcia, Ana
    Chao, Richard
    Felip, Enriqueta
    LUNG CANCER, 2010, 70 (02) : 180 - 187
  • [2] A phase I dose escalation study of sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer (NSCLC)
    Reck, M.
    Frickhofen, N.
    Gatzemeier, U.
    Fuhr, H.
    Lanzalone, S.
    Lechuga, M. J.
    Wang, E.
    Chao, R.
    Felip, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Vorinostat in combination with gemcitabine and cisplatinum in patients with advanced non-small cell lung cancer (NSCLC): A Phase I dose-escalation study
    Tredaniel, J.
    Descourt, R.
    Moro-Sibilot, D.
    Misset, J.
    Gachard, E.
    Garcia-Vargas, J.
    Roben, E.
    Zalcman, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
    R D Kim
    S R Alberts
    C Peña
    I Genvresse
    A Ajavon-Hartmann
    C Xia
    A Kelly
    J E Grilley-Olson
    British Journal of Cancer, 2018, 118 : 462 - 470
  • [5] Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
    Kim, R. D.
    Alberts, S. R.
    Pena, C.
    Genvresse, I.
    Ajavon-Hartmann, A.
    Xia, C.
    Kelly, A.
    Grilley-Olson, J. E.
    BRITISH JOURNAL OF CANCER, 2018, 118 (04) : 462 - 470
  • [6] Raltitrexed ('Tomudex') and cisplatin in metastatic non-small cell lung cancer (NSCLC): Preliminary results of a Phase I dose-escalation study
    Manegold, C
    Buchholz, E
    Kloeppel, R
    Kreisel, C
    Smith, M
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S253 - S253
  • [7] Phase I dose-escalation study of vorinostat in combination with gemcitabine and cisplatinum in patients with advanced non-small-cell lung cancer (NSCLC)
    Teixeira, L.
    Descourt, R.
    Moro-Sibilot, D.
    Misset, J. L.
    Gachard, E.
    Rizvi, S.
    Roben, E.
    Zalcman, G.
    EJC SUPPLEMENTS, 2009, 7 (02): : 554 - 554
  • [8] Vorinostat in combination with gemcitabine plus platinum in patients with advanced non-small-cell lung cancer: A phase I, dose-escalation study
    Misset, J.
    Tredaniel, J.
    Descourt, R.
    Morot-Sibilot, D.
    Zalcman, G.
    Gachard, E.
    Garcia-Vargas, J.
    Rizvi, S.
    Reiser, D.
    Roben, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Gemcitabine plus cisplatin in advanced non-small cell lung cancer (NSCLC): A phase II study
    Orlandi-Jorquera, L
    Orlandi, F
    Galaz, P
    Gamargo, C
    Salman, P
    Yanez, M
    ANNALS OF ONCOLOGY, 1998, 9 : 101 - 101
  • [10] CONCURRENT CHEMORADIOTHERAPY WITH TOMOTHERAPY IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): PHASE I, DOSE-ESCALATION STUDY
    Bearz, Alessandra
    Minatel, Emilio
    Abu Rumeileh, Imad
    Gobitti, Carlo
    Baresic, Tanja
    Drigo, Annalisa
    Talamini, Renato
    Vaccher, Emanuela
    Santarossa, Sandra
    Franchin, Gianni
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1553 - S1553
12345